Vical Inc (NASDAQ:VICL)

1.47
Delayed Data
As of Apr 20
 -0.07 / -4.55%
Today’s Change
1.32
Today|||52-Week Range
3.70
-19.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$20.2M

Company Description

Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.

Contact Information

Vical, Inc.
10390 Pacific Center Court
San Diego California 92121-4340
P:(858) 646-1100
Investor Relations:
(858) 646-1127

Employees

Shareholders

Other institutional37.38%
Mutual fund holders11.65%
Individual stakeholders10.56%

Top Executives

Vijay B. SamantPresident, Chief Executive Officer & Director
Keith D. HallVice President-Operations
Anthony Alan RamosChief Financial & Accounting Officer
Larry SmithSenior Vice President-Research
Mammen P. MammenSenior Vice President-Clinical Development